JPWO2022165204A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022165204A5
JPWO2022165204A5 JP2023544229A JP2023544229A JPWO2022165204A5 JP WO2022165204 A5 JPWO2022165204 A5 JP WO2022165204A5 JP 2023544229 A JP2023544229 A JP 2023544229A JP 2023544229 A JP2023544229 A JP 2023544229A JP WO2022165204 A5 JPWO2022165204 A5 JP WO2022165204A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
administered
apraglutide
gvhd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507324A (ja
JP2024507324A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014349 external-priority patent/WO2022165204A1/en
Publication of JP2024507324A publication Critical patent/JP2024507324A/ja
Publication of JPWO2022165204A5 publication Critical patent/JPWO2022165204A5/ja
Publication of JP2024507324A5 publication Critical patent/JP2024507324A5/ja
Pending legal-status Critical Current

Links

JP2023544229A 2021-01-28 2022-01-28 移植片対宿主病の治療のための組成物および方法 Pending JP2024507324A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142905P 2021-01-28 2021-01-28
US63/142,905 2021-01-28
US202163248074P 2021-09-24 2021-09-24
US63/248,074 2021-09-24
PCT/US2022/014349 WO2022165204A1 (en) 2021-01-28 2022-01-28 Compositions and methods for the treatment of graft versus host disease

Publications (3)

Publication Number Publication Date
JP2024507324A JP2024507324A (ja) 2024-02-19
JPWO2022165204A5 true JPWO2022165204A5 (https=) 2025-02-05
JP2024507324A5 JP2024507324A5 (https=) 2025-02-05

Family

ID=80461100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544229A Pending JP2024507324A (ja) 2021-01-28 2022-01-28 移植片対宿主病の治療のための組成物および方法

Country Status (11)

Country Link
US (3) US20220233645A1 (https=)
EP (2) EP4635509A1 (https=)
JP (1) JP2024507324A (https=)
KR (1) KR20230167019A (https=)
AU (1) AU2022212119A1 (https=)
BR (1) BR112023014978A2 (https=)
CA (1) CA3206093A1 (https=)
ES (1) ES3044110T3 (https=)
IL (1) IL304675A (https=)
MX (1) MX2023008793A (https=)
WO (1) WO2022165204A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025208047A1 (en) * 2024-03-28 2025-10-02 Vectivbio Ag Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8421271B2 (en) * 2009-08-31 2013-04-16 General Electric Company Apparatus for transferring energy using onboard power electronics and method of manufacturing same
EP2314616A1 (en) 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
EP3924369A1 (en) * 2019-02-11 2021-12-22 OPKO Biologics Ltd. Long-acting glp-2 analogs
KR20230038187A (ko) 2020-06-09 2023-03-17 벡티브바이오 에이지 아프라글루타이드의 제조, 제형화 및 투여

Similar Documents

Publication Publication Date Title
Plautz et al. Systemic T cell adoptive immunotherapy of malignant gliomas
JP7105188B2 (ja) 幹細胞移植方法
JP2018502117A5 (https=)
US11912780B2 (en) Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
Bearman et al. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4–9 involved axillary lymph nodes
Abraham et al. Cellular therapy for sickle cell disease
JPWO2022165204A5 (https=)
Lee et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin
Rowe Graft-versus-disease effect following allogeneic transplantation for acute leukaemia
Ballen et al. Cellular immune therapy for refractory cancers: novel therapeutic strategies
ES2371635T3 (es) Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes.
KR101694554B1 (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
Antin Approaches to graft‐vs‐host disease
WO2020219861A1 (en) Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
Ganich et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in Crohn’s disease
Ross Treatment of gastrointestinal acute graft-versus-host disease
Sun et al. Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus
Bingham et al. High dose immunosuppressive therapy and stem cell transplantation in autoimmune and inflammatory diseases
Moore et al. Stem cell transplantation for autoimmune diseases
Magliocca et al. Undifferentiated murine embryonic stem cells are unable to induce portal tolerance but may possess immune privilege
Ramirez et al. Anti-IL2 induction in liver trasplantation with 93% rejection free and 97% patient and graft survival at 24 months
Kröger 40 Allogeneic stem cell transplantation in MDS: reduced intensity conditioning and donor lymphocyte infusion
JP2004256444A (ja) 悪性腫瘍の治療方法
Jochum et al. Donor specific transfusion and either methotrexate or CD154-blockade before transplant improves rates of sustained engraftment in dogs conditioned with 100 cGy total body irradiation
Guthrie et al. CAR-T CELL THERAPY: A REVOLUTIONARY CANCER TREATMENT